Drug Sales See Minimal Climb in 2008

May 2009
Pharmaceutical Representative;May2009, Vol. 39 Issue 5, p8
The article reports on the slow increase of sales in pharmaceutical industry in the U.S. in 2008. Based on data of IMS Health Inc., Pfizer Inc.'s sales has decreased to $20.5 billion in 2008 from $23.6 billion in 2007. In addition, it reveals that lipid regulators are the most prescribed drugs in the year while antipsychotics are the most salable drugs in therapeutic class. Diana Conmy of IMS states that the industry has able to weather the crisis due to the importance of drugs to consumers.


Related Articles

  • World pharma sales on the up.  // PharmacoEconomics & Outcomes News;2/10/2007, Issue 521, p10 

    The article reports on the growth of pharmaceutical sales through retail pharmacies in several key markets in the world in the year ending November 2006. According to the data released by IMS Health, a 4% turnover increase was posted by France, Italy, Spain and Great Britain. The revenue...

  • Top Drugs.  // Pharmaceutical Executive;Jun2008, Vol. 29 Issue 6, p38 

    The article presents the lists of the pharmaceutical products that topped the sales market for 2007 in the U.S. According to the IMS Health Inc., the leading product has achieved once again by the Lipitor of Pfizer Inc., followed by Nexium and Seroquel. The annual review also shows that the...

  • Executive Summary.  // U.S. Pharma & Healthcare Report;Q1 2009, p6 

    The article presents an update on the performance of the pharmaceutical and healthcare industries in the U.S. as of the first quarter of 2009. According to IMS Health, the credit crunch has affected the healthcare sector, with prescription volume growth declining in the first and second quarters...

  • Rx sales growth slows up.  // Medical Marketing & Media;Mar2005, Vol. 40 Issue 3, p8 

    Reports that the prescription drug sales in 2004 grew at their slowest rate, according to a survey conducted by IMS Health Inc. in the U.S. Total sales; Percentage of the sales increase; Factors affecting the growth of drug sales.

  • the Pharm Exec 50.  // Pharmaceutical Executive;May2009, Vol. 29 Issue 5, p68 

    The article reports on the top 50 pharmaceutical companies accounted for prescription drug sales of about $558 billion in the U.S. It states that the top 50 companies are those that reach a double-digit growth in their sales despite of the recession. Among the top 50 companies are Pfizer Inc.,...

  • Cos. prepare for the dive off the patent cliff. DEARMENT, ALARIC // Drug Store News;12/14/2009, Vol. 31 Issue 15, p54 

    The article reports on the challenges faced by branded drug companies in the U.S. over the next decade when several drugs which have generated billions of dollars in revenue in the U.S. and abroad will lose patent protection. It is reported that, Pfizer Inc. earned 13.65 billion dollars globally...

  • BY THE NUMBERS.  // Modern Healthcare;3/22/2004, Vol. 34 Issue 12, p9 

    Presents information on the growth of global pharmaceutical sales in 2003 according to IMS Health. Percentage of the growth of global pharmaceutical sales; Comparison between the sales of the best-selling drugs in 2002 and 2003; Sales performance of the cholesterol-lowering drug Lipitor from...

  • Despite patent cliff, some opportunities await in pipeline. Baltazar, Amanda // Drug Store News;8/10/2009, Vol. 31 Issue 9, p60 

    The article reports on the opportunities for generic products despite their negative performance in the pharmaceutical industry due to patent expiration in the U.S. IMS Health Inc. reveals that generic products accounted 63.7% for the total pharmaceutical market volume. However, the patents of...

  • Worldwide sales of pharmaceutical drugs reach $434 billion. Martinez, Marialba // Caribbean Business;11/20/2003, Vol. 31 Issue 46, p18 

    Reports on the findings by IMS Health on worldwide sales of pharmaceutical drugs for the first six months of 2003. Total sales value; List of the top-selling drug firms; Top positions by Pfizer Inc., GlaxoSmithKline and Merck & Co.; Top sales by anti-infectives; Conditions and prospects of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics